7. Neurooncology Program - Darell D. Bigner, M.D., Ph.D., Program Leader; Allan Friedman, M.D. and Henry Friedman, M.D., Co-Leaders The Neurooncology Program has almost doubled in size from the last competitive submission to a total of 37 Ira.embers, consisting of basic, translational and clinical investigators. The common interests of the program are primary malignant brain tumors of adults and children. The scientific goals arc:
Aim 1 : to conduct epidemiological and molecular epidemiological studies to investigate etiology and to identify populations at greater and lesser risk for development of malignant brain tumors in adults and children;
Aim 2 : to determine molecular mechanisms of transformation, altered growth control, and invasion of malignant brain tumors of adults and children;
Aim 3 the identification of new drugs active against primary brain tumors of adults and children, the determination of mechanisms of drug resistance in primary brain tumors, and institution of methods to overcome drug resistance;
Aim 4 the development of monoclonal antibodies and recombinant DNA antibody fragments reactive with molecular targets, primary brain tumors, and the development of immunoconjugates for brain tumor treatment;
Aim 5 : the development of new radiolabeling technology for peptides and monoclonal antibodies and !their fragments and the introduction of s-emitters, such as 211-Astatine into clinical trial for brain tumor patients and the beta emitter lutetium 177;
Aim 6 : the development of cell-mediated immunotherapy and dendritic-based vaccine trials for brain tumors;
Aim 7 : development of oncolytic poliovirus with no neurovirulence, but retention of oncolytic capacity for gliomas into a reagent that can be used for therapy of malignant gliomas and neoplastic meningitis from breast cancer;
Aim 8 : development of imaging capabilities with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) for improved brain tumor diagnosis and radiation dosimetry in radiolabeled antibody, chemotherapy and small molecular inhibitor clinical trials in brain tumor patients;
Aim 9 : the design and execution of Phase I, Phase II, and Phase III clinical trials in primary and metastatic brain tumors in adults and children, based on laboratory discoveries within the Program and the execution of clinical trials for improvement of quality of life in brain tumor patients. Investigators in the Program hold 48 peer-reviewed grants from NCI or NIH and the total direct cost funding of investigators in the Program is $21,500,000. Dr. Henry Friedman, James P. Powell, Jr. Professor of Pediatric Oncology and Chief, Division of Neurooncology and Dr. Allan Friedman, Guy L. Odom Professor of Neurosurgery and Chief of Neurosurgery, the Clinical Co-directors of the Brain Tumor Center, who have long led the clinical aspects of the program, join Dr. Darell Bigner as Co-Leaders of the Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-34
Application #
7726647
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-01-01
Budget End
2008-12-31
Support Year
34
Fiscal Year
2008
Total Cost
$25,090
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :

Showing the most recent 10 out of 513 publications